Clinical trials: Cardiovascular Diseases
Thromboembolism, Arthroplasty, Replacement, Hip
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Open, prospective, uncontrolled, observational cohort study.
- Trial name
- NCT00967447
- Where
- 28 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma
Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3
This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma.
- Trial name
- NCT00866138
- Testing
- masitinib (AB1010)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- AB Science
Hypertension, CKD - Chronic Kidney Disease
A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease
Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of the six-channel radiofrequency（RF) renal denervation system-comprising the six-channel radiofrequency…
- Trial name
- NCT07130955
- Testing
- Six-channel RF Renal Denervation System
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Atrial Fibrillation
Performance of QDOT Micro™ Catheter With nGEN Generator for Patients With AFIB.
This workflow study will further evaluate the acute performance and safety of the QDOT MICRO™ catheter in a clinical setting used in combination with nGEN Generator. Subjects will be followed for 7 days post procedure.
- Trial name
- NCT04545619
- Testing
- QDOT MICRO System
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Biosense Webster, Inc.
Dyslipidemia, Coronary Heart Disease
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
- Trial name
- NCT00300430
- Testing
- ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
- Where
- United States
- Volunteers
- 1,911 people
- Sponsor
- Abbott
Arthroplasty, Replacement, Hip, Thrombosis
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the…
- Trial name
- NCT00107900
- Testing
- DU-176b
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Daiichi Sankyo
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell, Waldenstrom Macroglobulinemia
- Trial name
- NCT05172700
- Testing
- Pirtobrutinib
- Sponsor
- Loxo Oncology, Inc.
Post Thrombotic Syndrome
Long-Term Post Thrombotic Syndrome Assessment (CELEST Long Term).
The CELEST Long term is a prospective study, assessing the very long term risk of post thrombotic syndrome (PTS) in patients enrolled in the CELEST double-blind RCT.
- Trial name
- CELEST-LT (NCT06046807)
- Testing
- Phone call
- Where
- France
- Volunteers
- 288 people
- Sponsor
- Laboratoires Innothera
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort…
- Trial name
- NCT07217184
- Testing
- Belantamab mafodotin, Isatuximab
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Congestive Heart Failure
SyncAV Post-Market Trial
The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices…
- Trial name
- SyncAV (NCT04100148)
- Testing
- SyncAV programmed ON, Fixed AV delay
- Where
- 104 sites in United States, Austria and 23 more
- Volunteers
- 1,686 people
- Sponsor
- Abbott Medical Devices
Relapsed or Refractory Multiple Myeloma
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed…
- Trial name
- NCT06500507
- Testing
- QLS4131 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Abdominal Aortic Aneurysm (AAA)
Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms
The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).
- Trial name
- NCT02009644
- Testing
- Subjects who receive the Treovance stent-graft
- Where
- 29 sites in United States
- Volunteers
- 158 people
- Sponsor
- Bolton Medical
Atherosclerosis, Coronary Artery Disease
ARISE - Aggressive Reduction of Inflammation Stops Events
To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events.
- Conditions
- Atherosclerosis, Coronary Artery Disease, Myocardial Infarction, Unstable Angina
- Trial name
- NCT00066898
- Testing
- AGI-1067
- Where
- 219 sites in United States, Canada and 2 more
- Volunteers
- 6,000 people
- Sponsor
- AtheroGenics
Essential Hypertension
The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.
The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.
- Trial name
- SORT (NCT01295021)
- Where
- 97 sites in India
- Volunteers
- 1,514 people
- Sponsor
- AstraZeneca
Upper Limb Weakness Due to Central Neurologic Injury, Upper Limb Weakness Due to Peripheral Neurologic Injury
mGain - sEMG-based Gamified Therapy for Improved Upper Limb Rehabilitation
The purpose of this Phase I study is to conduct a pilot clinical trial using a mobile app-connected, wire-free surface electromyography (sEMG) system, called mGain, that provides biofeedback-based therapy in individuals with…
- Conditions
- Upper Limb Weakness Due to Central Neurologic Injury, Upper Limb Weakness Due to Peripheral Neurologic Injury, Upper Limb Weakness Due to Nerve Reconstruction, Upper Limb Weakness Due to Tendon Transfer Surgery
- Trial name
- NCT06023316
- Testing
- mGain system
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Orthocare Innovations, LLC
Chronic Heart Failure, Central Sleep Apnea
French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS)
The purpose of FACE study is to provide in routine practice complementary long-term data on the mortality and morbidity of Chronic Heart Failure (CHF) patients with Central Sleep Apnea eligible for Adaptative Servo-Ventilation…
- Trial name
- FACE (NCT01831128)
- Testing
- ASV Treatment
- Where
- 18 sites in France
- Volunteers
- 509 people
- Sponsor
- ResMed
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit
COMPASSION S3 Post-Approval Study
This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve…
- Conditions
- Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
- Trial name
- NCT04860765
- Testing
- SAPIEN 3 THV
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Edwards Lifesciences
Coronary Artery Disease
A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers
In this study, the relative bioavailability of different formulations of AZD5718 will be determined in order to compare it with the formulation used in a previous Phase 2a study and confirm appropriate drug exposure.
- Trial name
- NCT03420092
- Testing
- Form 1 of AZD5718 tablets, Form 2 of AZD5718 tablets, Form 3 of AZD5718 tablets
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Transthyretin Amyloid Cardiomyopathy
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that…
- Trial name
- NCT07690436
- Where
- 20 sites in United States, Germany and 3 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus…
- Trial name
- CVD-REAL (NCT02993614)
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 99,999 people
- Sponsor
- AstraZeneca